Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company focused on developing gene-editing therapies. Today, NTLA experienced a strong bearish movement in the stock market.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Apr 27, 2026 18:55

• NTLA stock had a bearish movement despite positive late-stage trial data for its gene-editing therapy for hereditary angioedema (HAE).
• The market may have reacted negatively due to profit-taking by investors who were anticipating a bullish run following the positive trial results.
• Despite the positive news, the stock might have been impacted by the overall market sentiment or profit concerns, leading to the bearish movement.
• It's essential to consider that short-term market fluctuations do not always reflect the long-term potential of a company's innovative therapies.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics (NTLA) shares surged pre-market following positive late-stage trial data for its gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The therapy met primary and secondary endpoints, with 62% of patients free of HAE attacks, compared to 11% on placebo. Intellia has initiated a rolling Biologics License Application submission to the FDA and aims for a U.S. launch in the first half of 2027.

https://stocktwits.com/news-articles/markets/equity/ntla-stock-soars-intellia-positive-gene-therapy-trial/cZBNFouRe2C

Intellia Therapeutics Initiates Rolling Submission of

Intellia Therapeutics has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), a one-time gene-editing treatment for hereditary angioedema (HAE). This submission follows positive Phase 3 HAELO trial results, which showed lonvo-z freed most patients from HAE attacks and ongoing therapy. The company expects to complete the BLA by the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027.

https://www.globenewswire.com/news-release/2026/04/27/3281478/0/en/intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment-for-hereditary-angioedema.html

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics announced positive topline results from its global Phase 3 HAELO clinical trial for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), marking the first Phase 3 data for an in vivo gene editing therapy. The trial met its primary and all key secondary endpoints, demonstrating that a single dose of lonvo-z significantly reduced HAE attacks and freed most patients from ongoing therapy for six months. Intellia has initiated a rolling Biologics License Application (BLA) submission with the U.S. FDA, anticipating a potential U.S. launch in the first half of 2027 if approved.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics stock surged 19.3% after hours ahead of the upcoming release of top-line Phase 3 data for its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran, for hereditary angioedema. The company expects to announce results from its HAELO trial on Monday, April 27, 2026, which could lead to a U.S. biologics license application later this year. Investors will be closely watching for attack-rate reduction and safety data, especially given past clinical hold issues with another program.

https://ts2.tech/en/intellia-therapeutics-stock-jumps-after-hours-ahead-of-first-phase-3-in-vivo-crispr-readout/

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Hold" by Brokerages

Intellia Therapeutics (NASDAQ:NTLA) has received a "Hold" consensus rating from twenty brokerages, with an average one-year price target of $19.52. Despite this, some analysts have recently upgraded the stock or increased price targets, reflecting rising enthusiasm. The company recently beat quarterly revenue and EPS estimates but remains unprofitable.

https://www.marketbeat.com/instant-alerts/intellia-therapeutics-inc-nasdaqntla-given-consensus-rating-of-hold-by-brokerages-2026-04-25/

Trending Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Packaging Corporation of America ($PKG) Stock Forecast: Up 3.1% Today

Intellia Therapeutics, Inc. Price History

27.03.2026 - NTLA Stock was down 5.1%

• NTLA stock had a bearish movement despite positive late-stage trial data for its gene-editing therapy for hereditary angioedema (HAE).
• The market may have reacted negatively due to profit-taking by investors who were anticipating a bullish run following the positive trial results.
• Despite the positive news, the stock might have been impacted by the overall market sentiment or profit concerns, leading to the bearish movement.
• It's essential to consider that short-term market fluctuations do not always reflect the long-term potential of a company's innovative therapies.

31.02.2026 - NTLA Stock was up 5.2%

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

22.03.2026 - NTLA Stock was up 6.6%

• Analysts have given NTLA a moderate buy rating with an average price target of $21.25, indicating positive sentiment towards the company's future prospects.
• Despite recent share price volatility, the company's strong year-to-date and one-year performance, along with a narrative of rapid revenue growth, have contributed to the bullish movement.
• The market's interest in NTLA's valuation, driven by demographics and genetic conditions supporting its value, coupled with potential risks from trial disappointments or payer pushback, may have influenced the positive market sentiment.
• The amendment of by-laws and designation of federal district courts as the exclusive forum for Securities Act claims could also be seen as a positive development, enhancing shareholder rights and potentially boosting investor confidence in the stock.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

21.03.2026 - NTLA Stock was up 6.2%

• NTLA stock saw a positive trend today, possibly influenced by its strong year-to-date and one-year performance, as well as favorable analyst target prices and valuation models.
• The market shows confidence in NTLA's potential for revenue growth and its capacity to meet the increasing demand for genetic therapies.
• Despite risks like disappointing trial outcomes or cost challenges, investors are currently drawn to NTLA because of its promising future and valuation indicators.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

24.03.2026 - NTLA Stock was down 10.3%

• The bearish movement in NTLA stock today could be attributed to the following factors:
• Despite the recent positive momentum and market leadership demonstrated by Intellia Therapeutics, investors might be taking profits after a significant 20% increase in the stock price over the past three months.
• The mixed short-term returns and recent share price volatility, coupled with potential risks such as disappointing trial results or payer pushback on costs, could be causing some uncertainty among investors.
• While analysts have provided a moderate buy rating and set an average price target of $21.25, the discrepancy between the current share price and the estimated fair value according to a DCF model might be contributing to the downward pressure on the stock.
• Investors may also be cautious due to the company's amendment of its by-laws and the designation of federal district courts as the exclusive forum for Securities Act claims, which could introduce legal uncertainties impacting the stock's performance.

13.03.2026 - NTLA Stock was up 5.9%

• Intellia Therapeutics (NTLA) saw a significant increase of 14.2% in its stock price today.
• The rise in stock price is linked to the FDA lifting clinical holds on Intellia's MAGNITUDE trials, which has provided regulatory clarity and bolstered investor confidence.
• An analyst upgrade from Jones Trading further boosted optimism about Intellia, emphasizing the potential of its gene editing programs for conditions like ATTR amyloidosis and HAE.
• The market is reflecting expectations for future growth for Intellia, as evidenced by its high Price/Sales ratio, indicating positive outlook on the company's prospects in the gene editing industry.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.